NCT04094766 - Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia | Biotech Hunter

Timeline

Start Date

August 1, 2017

Primary Completion Date

August 30, 2020

Study Completion Date

August 30, 2020

Conditions

Refractory B Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia

Interventions

DRUG

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.

Trial Locations (1)

710000

Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an